REG - Novacyt S.A. - Notice of Results and Investor Presentation

Novacyt SAAnnouncement

15/09/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220915:nRSO5179Za&default-theme=true

RNS Number : 5179Z  Novacyt S.A.  15 September 2022

Novacyt S.A.

 

("Novacyt" or the "Company")

 

Notice of Half Year 2022 Results and Investor Presentation

 

Paris, France and Camberley, UK - 15 September 2022 - Novacyt S.A. (EURONEXT
GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical
diagnostics, announces that it will report its unaudited financial results for
the six months ended 30 June 2022 on Thursday, 29 September 2022.

 

Investor webinar

An investor webinar presentation by David Allmond, Chief Executive Officer,
and James McCarthy, Chief Financial Officer, will take place at 12pm BST on
Thursday, 29 September 2022.

 

The webinar is open to all existing and potential investors and will consist
of a presentation followed by a Q&A session, held on the Investor Meet
Company platform. Questions can be submitted pre-event via your Investor Meet
Company dashboard up until 9am the day before the meeting or at any time
during the live presentation. Automated French subtitling will be available
throughout the presentation. The presentation slides will be made available on
Novacyt's website at the time of the webcast.

 

Investors can sign up to Investor Meet Company for free and add to meet
NOVACYT S.A. via:

 

https://www.investormeetcompany.com/novacyt-sa/register-investor
(https://www.investormeetcompany.com/novacyt-sa/register-investor)

 

Investors who already follow NOVACYT S.A. on the Investor Meet Company
platform will automatically be invited.

- End -

 

 

Contacts

Novacyt SA

David Allmond, Chief Executive Officer

James McCarthy, Chief Financial Officer

+44 (0)1276 600081

 

SP Angel Corporate Finance LLP (Nominated Adviser and Broker)

Matthew Johnson / Charlie Bouverat (Corporate Finance)

Vadim Alexandre / Rob Rees (Corporate Broking)

+44 (0)20 3470 0470

 

Numis Securities Limited (Joint Broker)

Freddie Barnfield / James Black

+44 (0)20 7260 1000

 

Allegra Finance (French Listing Sponsor)

Rémi Durgetto / Yannick Petit

+33 (1) 42 22 10 10

r.durgetto@allegrafinance.com (mailto:r.durgetto@allegrafinance.com) /
y.petit@allegrafinance.com (mailto:y.petit@allegrafinance.com)

 

 

FTI Consulting (International)

Victoria Foster Mitchell / Alex Shaw

+44 (0)20 3727 1000

victoria.fostermitchell@fticonsulting.com
(mailto:victoria.fostermitchell@fticonsulting.com) /
Alex.Shaw@fticonsulting.com (mailto:Alex.Shaw@fticonsulting.com) /
Novacyt.group@fticonsulting.com (mailto:Novacyt.group@fticonsulting.com)

 

FTI Consulting (France)

Arnaud de Cheffontaines

+33 (0)147 03 69 48

arnaud.decheffontaines@fticonsulting.com
(mailto:arnaud.decheffontaines@fticonsulting.com)

 

About Novacyt Group

The Novacyt Group is an international diagnostics business generating an
increasing portfolio of in vitro and molecular diagnostic tests. Its core
strengths lie in diagnostics product development, commercialisation, contract
design and manufacturing. The Company supplies an extensive range of
high-quality assays and reagents worldwide. The Group directly serves
microbiology, haematology and serology markets as do its global partners,
which include major corporates.

 

For more information, please refer to the website: www.novacyt.com
(http://www.novacyt.com)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORDGGDCCXBDGDS